Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone

Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone

John F Kokai-Kun,1 Chenxiong Le,1 Kenneth Trout,1 Julia L Cope,2 Nadim J Ajami,2 Andrew J Degar,2 Sheila Connelly1 1Synthetic Biologics, Inc., Rockville, MD, USA; 2Diversigen, Inc., Houston, TX, USACorrespondence: Sheila Connelly Email sconnelly@syntheticbiologics.comIntroduction: Intravenous (IV) &...

Full description

Bibliographic Details
Main Authors: Kokai-Kun JF, Le C, Trout K, Cope JL, Ajami NJ, Degar AJ, Connelly S
Format: Article
Language:English
Published: Dove Medical Press 2020-07-01
Series:Infection and Drug Resistance
Subjects:
oral β-lactamase
ceftriaxone
gut resistome
whole genome shotgun sequencing
clinical study
antimicrobial resistance
Online Access:https://www.dovepress.com/ribaxamase-an-orally-administered-beta-lactamase-diminishes-changes-to-peer-reviewed-article-IDR

Internet

https://www.dovepress.com/ribaxamase-an-orally-administered-beta-lactamase-diminishes-changes-to-peer-reviewed-article-IDR

Similar Items